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Abstract: Phenylketonuria and tyrosinemia type 1 are treated with dietary phenylalanine (Phe)
restriction. Aspartame is a Phe-containing synthetic sweetener used in many products, including
many ‘regular’ soft drinks. Its amount is (often) not declared; therefore, patients are advised
not to consume aspartame-containing foods. This study aimed to determine the variation in
aspartame concentrations and its Phe-containing degradation products in aspartame-containing
soft drinks. For this, an LC–MS/MS method was developed for the analysis of aspartame, Phe,
aspartylphenylalanine, and diketopiperazine in soft drinks. In total, 111 regularly used soft drinks
from 10 European countries were analyzed. The method proved linear and had an inter-assay
precision (CV%) below 5% for aspartame and higher CVs% of 4.4–49.6% for the degradation products,
as many concentrations were at the limit of quantification. Aspartame and total Phe concentrations
in the aspartame-containing soft drinks varied from 103 to 1790 µmol/L (30–527 mg/L) and from
119 to 2013 µmol/L (20–332 mg/L), respectively, and were highly variable among similar soft drinks
bought in different countries. Since Phe concentrations between drinks and countries highly vary,
we strongly advocate the declaration of the amount of aspartame on soft drink labels, as some drinks
may be suitable for consumption by patients with Phe-restricted diets.
Keywords: aspartame; phenylalanine; aspartylphenylalanine; diketopiperazine; soft drinks;
phenylketonuria; tyrosinemia type 1
1. Introduction
Several inborn errors of metabolism require monitoring of daily dietary phenylalanine (Phe)
intake. These include disorders causing hyperphenylalaninemia and disorders treated with
2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). A well-known example of a
disorder associated with hyperphenylalaninemia is phenylketonuria (PKU; McKusick 261600), caused
by a deficiency of the enzyme phenylalanine hydroxylase [1,2]. This leads to a diminished or sometimes
even blocked conversion of Phe into tyrosine (Tyr). The resulting high Phe concentrations in blood and
brain are detrimental for neurological development [3]. Therefore, the treatment of PKU and some other
hyperphenylalaninemic disorders largely consists in dietary Phe restriction. Disorders treated with
NTBC, on the other hand, include tyrosinemia type 1 (TT1; McKusick 276700) and alkaptonuria (AKU;
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McKusick 203500) [4–6], which are both caused by a deficiency of an enzyme in the Tyr degradation
pathway. NTBC blocks the activity of the upstream enzyme 4-hydroxyphenylpyruvate dioxygenase,
thereby preventing the accumulation of toxic products in TT1 and AKU patients. This, however, leads
to high Tyr concentrations, thereby necessitating a dietary restriction of Tyr and its precursor Phe.
The dietary treatment of the mentioned diseases consists in a low dietary intake of natural proteins
combined with an amino acid mixture devoid of Phe (and sometimes Tyr). Phe is present in variable
amounts in different food products, with high Phe concentrations in meat, poultry, fish, eggs, soy
products, dairy products, some vegetables, and, of interest, aspartame (APM).
APM is a synthetic sweetener approximately 100–200 times sweeter than sucrose [7]. Therefore,
it is a low-caloric alternative for common sweeteners such as sucrose and is nowadays used in food
products, particularly in soft drinks [8]. APM has been approved by the Food and Drug Administration
(FDA) as a food additive (E-951), and the use of APM in products needs to be documented on the
label. APM is a methylester of the dipeptide aspartate and Phe, and therefore a source of Phe. Patients
with Phe-restricted diets are therefore recommended not to consume APM-containing soft drinks.
Unfortunately, it is difficult to find specific information on the APM contents in soft drinks, as it is not
mandatory for manufacturers to declare the amount of APM.
There are some publications on APM concentrations in a small number of soft drinks [9–16].
These studies analyzed APM mostly in addition to other sweeteners to investigate consumption or
to study the instability of APM. APM is instable at high temperatures and at high and very low pH,
which cause its degradation to other components, including 5-benzyl-3,6-dioxo-2-piperazine acetic
acid [diketopiperazine (DKP)], aspartate, aspartylphenylalanine (Asp–Phe), and Phe [7,17]. Most of
these degradation products are also sources of Phe. Patients with Phe-restricted diets would benefit
from information on the amount of APM and other Phe-containing metabolites in soft drinks, as some
soft drinks may be suitable as part of their diets.
This study aimed to investigate the concentrations of APM and most of its Phe-containing
degradation products, including DKP, Asp–Phe, and Phe, in regularly used soft drinks from European
countries. For this purpose, we developed a liquid chromatography–Tandem mass spectrometry
(LC–MS/MS) method for the simultaneous quantitative analysis of APM and its metabolites.
2. Materials and Methods
2.1. Chemicals and Reagents
L-APM was obtained from the United States Pharmacopeia (Basel, Switzerland), L-APM-d5
from Toronto Research Chemicals (North York, ON, Canada), aspartic acid, aspartylphenylalanine,
Phe, and diketopiperazine were obtained from Sigma-Aldrich Corporation (Saint Louis, MO, USA).
Methanol ≥99.98% and formic acid 99% were obtained from Biosolve (Valkenswaard, The Netherlands),
and HCl 37% from Merck Darmstadt.
2.2. Samples
Contact persons in 10 European countries were approached to send us bottles or cans of soft
drinks, obtained from local supermarkets. To study within- and between-batch variation, three samples
from three batches of Coca Cola zero and Fanta Orange zero (i.e., 9 samples, 3 batches per soft drink)
were bought in The Netherlands and were analyzed in duplicate.
2.3. Analyses
Calibration solutions, quality control samples (4 selected soft drinks), and soft drinks (2 mL) were
de-gassed for 20 min in an ultrasonic bath at 10 ◦C. Then, 10 µL of either sample or calibration solution
was subsequently added to 1490 µL of internal standard solution (6.7 µM APM-D5 in 0.1 M HCl)
and vortexed for 10 s. For the analysis, 5 µL of this sample was injected onto a high-performance
liquid chromatography (HPLC) column. All samples were analyzed in duplicate using a HPLC (LC20;
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Shimadzu, Kyoto, Japan) coupled to a triple quadrupole mass spectrometer with an electrospray
ionization source (API-3200, SCIEX, Framingham, MA, USA). LC–MS/MS analysis was carried out
using a Kinetex Biphenyl (2.6 µm pore size, 150 × 4.6 mm) analytical column coupled to a Kinetex
Biphenyl (2.6 µm pore size, 2 × 4.6 mm) guard column (Phenomenex, Torrance, CA, USA). Separation
was achieved in 5 min by applying isocratic elution (40% mobile phase A: 0.1% formic acid in MilliQ
water and 60% mobile phase B: 100% methanol), at a flow rate of 0.6 mL/min and a column temperature
of 40 ◦C. Detection was achieved using positive-ion electrospray ionization in multiple reaction
monitoring mode, using the following transitions: m/z 295.2 > 235.3 for APM, m/z 300.2 > 125.2
for D5-APM, m/z 263.1 > 91.2 for DKP, m/z 281.2 > 166.3 for Asp–Phe, and m/z 166.1 > 120.2 for
Phe. The electrospray ionization source temperature was kept at 450 ◦C, the ion spray voltage at
4000 V, and nitrogen was used as the nebulizing gas. Data were analyzed using Analyst 1.6.2 (Sciex,
Framingham, MA, USA).
2.4. Validation
Four soft drinks with different amounts of the various metabolites were selected for precision
experiments. Intra-day precision was calculated from 10 replicates analyzed in a single analytical
run. Inter-assay variation was calculated from the samples analyzed in duplicate on 7 different days.
Precision was calculated as %CV = standard deviation/mean of replicates.
For linearity, an eight-point calibration curve in the concentration range of 0.00–3.45 µmol/L for
APM, 0.00–0.903 µmol/L for Phe, 0.00–0.576 µmol/L for DKP, and 0.00–0.746 µmol/L for Asp–Phe
dissolved in 0.1 M HCl was analyzed 7 times, including 1 time in random order and 1 time in high–low
order. Slope (K1), correlation coefficient (R), and CV were calculated to determine the linearity.
In addition, the calibration samples were diluted in two soft drinks to determine the effect of the soft
drink matrix on the analysis. The matrix effect and mean recovery were investigated by comparing the
slopes of the calibration curves, and a difference <15% was considered acceptable. The difference is
also the representative of the mean recovery of metabolites from the matrix.
The limit of detection (LOD) and the limit of quantification (LOQ) were calculated from the
7 calibration curves. The standard deviation of the y-intercepts and the mean slope of the regression
models were calculated. The LOD was defined as (3.3 × sd)/slope, whereas the LOQ was defined as
(10 × sd)/slope [18]. Carry over was determined by analyzing QC high (H) and QC low (L) 10 times in
a specific order; L1 L2 H1 H2 L3 H3 H4 L4 L5 L6 L7 H5 H6 L8 H7 H8 L9 H9 H10 L10 (EP Evaluator
12.0, Data Innovations LLC, South Burlington, Vermont, USA). The mean and standard deviation of
low-after-low (LL: L2, L5, L6 and L7) and low-after-high (LH: L3, L4, L8, L9 and L10) were calculated.
Carry over was considered present when mean LH −mean LL <3 × SD of LL.
The stability of APM and its metabolites was determined in duplicate in three soft drinks after
0, 1, 2, 3, 7, and 14 days of storage at ±37 ◦C, ±22 ◦C, ±2 ◦C, and ±−20 ◦C. Moreover, the stability of the
processed samples was assessed after 0, 2, 4, 8, 16, and 24 h of storage in the autosampler at 15 ◦C.
A deviation >15% from t = 0 was considered significant.
2.5. Statistics
The contents of APM and its metabolites were expressed in µmol/L. The total Phe amount in soft
drinks was calculated from the concentrations of APM and Phe-containing metabolites, as 1 mol of
APM or Phe-metabolite is equal to 1 mol of Phe. Within- and between-batch variation was calculated
as coefficients of variation (CV; standard deviation/mean) in percentage. In addition to this, differences
between batches were tested using Kruskal–Wallis tests. Statistical analyses were performed using
IBM SPSS Statistics 23rd version, and p-values < 0.05 were considered statistically significant.
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3. Results
3.1. Method Validation
The inter- and intra-assay precision of the newly developed method for the analysis of APM and its
degradation products were determined by analyzing four soft drinks, see Table 1. The method proved
linear in the concentration range of 0–3450 µmol/L for APM (R = 0.9995, CV = 0.03%), 0–900 µmol/L for
Phe (R = 0.9998, CV = 0.01%), 0–576 µmol/L for DKP (R = 0.9994, CV = 0.02%), and 0–746 µmol/L for
Asp–Phe (R = 0.9996, CV = 0.01%). The LOD/LOQ were 0.002/0.007 µmol/L for APM, 10/30 µmol/L for
Phe, 7/22 µmol/L for DKP, and 17/50 µmol/L for Asp–Phe. There was no carry-over (see Supplementary
Table S1). There was no matrix effect for the four components, the slopes of the calibration standards
diluted in soft drinks A and B were comparable (i.e., less than 15% different) to those of the standards
diluted in 0.1 M HCl, i.e., 94% (APM), 100% (Phe), 91% (DKP), and 110% (Asp/Phe) for soft drink
A and 96% (APM), 96% (Phe), 91% (DKP), and 101% (Asp/Phe) for soft drink B. These results also
represent the mean recoveries of the components. Results of the stability experiment are shown in
Table 2. Aspartame concentration considerably decreased when heated up to ±37 ◦C, whereas the
concentrations of the degradation products DKP and Asp–Phe increased at this temperature. The total
Phe concentration also decreased, but to a lower extent. The concentrations of aspartame and total Phe
were relatively stable at all other temperatures. DKP and to a lesser extent Asp–Phe concentrations
increased when the samples were kept heated up to ±37 ◦C or at room temperature. DKP concentration
increased in S-2 also when stored cooled or frozen until day 6, whereas no changes occurred in the
more concentrated sample (S-3) at these lower temperatures.
Table 1. Intra- and inter-assay precision of the method for the analysis of aspartame and its
degradation products.




Mean (µmol/L) 349.5 5.5 22.4 23.1 378.6
CV (%) 3.3% 8.1% 6.8% 1.8% 3.1%
Soft drink B
N = 10
Mean (µmol/L) 1559.0 12.3 30.4 25.1 1601.7
CV (%) 2.5% 3.7 7.6% 1.4% 2.4%
Soft drink C
N = 10
Mean (µmol/L) 2747.0 16.1 141.2 72.9 2878.5
CV (%) 3.8% 7.3% 3.3% 3.1% 3.8%
Soft drink D
N = 10
Mean (µmol/L) 634.2 9.7 86.4 86.2 816.5




Mean (µmol/L) 203.4 3.9 10.3 21.1 238.1
CV (%) 4.9% 38.6% 33.6% 14.4% 5.4%
Soft drink B
N = 14
Mean (µmol/L) 920.9 11.1 26.7 36.8 995.5
CV (%) 4.7% 23.8% 17.4% 12.0% 4.7%
Soft drink C
N = 14
Mean (µmol/L) 1664.3 4.1 77.0 139.2 1884.6
CV (%) 3.9% 49.6% 22.9% 11.9% 4.4%
Soft drink D
N = 14
Mean (µmol/L) 622.6 13.3 100.7 104.8 841.3
CV (%) 3.8% 22.3% 16.9% 11.4% 4.7%
APM, aspartame, Phe, phenylalanine, DKP, diketopiperazine, Asp–Phe, aspartylphenylalanine, CV, coefficient
of variation.
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Table 2. Stability experiment.
APM Phe DKP Asp–Phe Total Phe
S-1 S-2 S-3 S-1 S-2 S-3 S-1 S-2 S-3 S-1 S-2 S-3 S-1 S-2 S-3
Reference (µmol/L) Day 0 227.0 1008.0 1880.0 1.30 (<LOD) 7.30 (<LOD) 0.99 (<LOD) 0.00 (<LOD) 3.18 (<LOD) 54.1 22.9 24.3 121.0 249.9 1035.5 2055.1
Heated
±37 ◦C
Day 1 100% 100% 98% <LOD <LOD <LOD <LOD <LOD 129% 108% 112% 109% 101% 100% 100%
Day 6 79% 77% 78% <LOD <LOD <LOD <LOD <LOD 214% 96% 149% 131% 87% 83% 85%
Day 15 64% 64% 69% <LOD <LOD <LOD <LOD <LOD 375% 120% 217% 181% 79% 74% 84%
Room temp
±22 ◦C
Day 1 95% 99% 93% <LOD <LOD <LOD <LOD <LOD 101% 101% 114% 102% 96% 100% 94%
Day 6 104% 93% 90% <LOD <LOD <LOD <LOD <LOD 124% 124% 105% 103% 112% 95% 92%
Day 15 86% 93% 90% <LOD <LOD <LOD <LOD <LOD 153% 98% 146% 128% 90% 96% 94%
Cooled
±2 ◦C
Day 1 100% 99% 95% <LOD <LOD <LOD <LOD <LOD 101% 105% 110% 98% 101% 99% 95%
Day 6 97% 97% 93% <LOD <LOD <LOD <LOD <LOD 106% 79% 91% 95% 98% 98% 93%
Day 15 94% 90% 95% <LOD <LOD <LOD <LOD <LOD 108% 86% 103% 102% 95% 91% 96%
Frozen
±−20 ◦C
Day 1 93% 98% 98% <LOD <LOD <LOD <LOD <LOD 102% 95% 106% 102% 93% 98% 98%
Day 6 100% 94% 96% <LOD <LOD <LOD <LOD <LOD 105% 80% 87% 93% 101% 94% 96%
Day 15 95% 93% 96% <LOD <LOD <LOD <LOD <LOD 109% 86% 96% 96% 96% 94% 97%
S-1, S-2, and S-3 are the different soft drinks used in the stability experiment. Concentrations are expressed as a percentage relative to the concentration on day 0. Deviations of more than
15%, shown underlined and in bold, were considered significant. Concentrations were below the limit of detection (LOD) in all samples for Phe (<10 µmol/L) and in samples 1 and 2 for
DKP (<7 µmol/L) and therefore not suitable for investigation of (in)stability.
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3.2. Aspartame and its Metabolites in Soft Drinks across Europe
A total of 111 soft drinks in original cans or bottles were obtained from Belgium (n = 15), Denmark
(n = 2), Finland (n = 21), France (n = 4), Germany (n = 7), Spain (n = 7), Sweden (n = 4), The Netherlands
(n = 38), Turkey (n = 4), and the United Kingdom (n = 9). Sixteen soft drinks did not contain APM
according to their labels. APM and APM degradation products were measured using our validated
method. The results of APM and total Phe are shown in Figure 1. APM and total Phe were not
detectable in the 16 non-APM soft drinks.Nutrients 2020, 12, x FOR PEER REVIEW 7 of 11 
 
 
Figure 1. Aspartame and total phenylalanine contents of all 111 soft drinks. Specifics regarding the soft drinks and their countries of origin can be found in 
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APM, aspartame, Phe, phenylalanine. 
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The 111 soft drinks were divided into four subgroups; group A (orange drinks), group B (lemon
drinks), group C (cola drinks), and group D (other drinks). Similar drinks, such as diet, sugar-free,
or flavored versions, were clustered. APM, Phe, DKP, Asp–Phe, and total Phe concentrations for the
different groups are shown in Supplementary Table S2. The percentage of Phe that derived from
non-APM products amounted to a mean of 14% of total Phe, ranging from 4 to 51%.
3.3. Within- and Between-Batch Variation (Same Country)
Within-batch variations were 2.7, 2.6, 3.3% (APM) and 2.6, 2.7, 3.0% (total Phe) for the three
batches of Fanta Orange zero and 3.6, 1.7, 4.8% (APM) and 3.7, 1.6, 4.6% (total Phe) for the three batches
of Coca Cola zero. Figure 2 shows the variation in APM between the batches. Between-batch CV
were 3.8% (APM) and 4.2% (total Phe) for Fanta Orange zero and 3.6% (APM) and 3.4% (total Phe) for
Coca Cola zero. Kruskal–Wallis tests showed small, but significant differences in APM and total Phe
concentrations between the three batches of Fanta orange zero (p = 0.010 and p = 0.013). No significant
differences were observed between the three Coca Cola zero batches. Finally, there were no significant
differences between samples from the same batch.
3.4. Between-Batch Variation between Countries
Results for APM, degradation products, and total Phe of all soft drinks are shown in Supplementary
Table S2. Large between-country variations were observed.
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natural protein is considered to equal approximately 50 mg (or 303 µmol) of Phe [20]. Protein 
tolerance, however, can differ significantly among patients, depending on, e.g., residual enzyme 
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4. Discussion
This study developed and validated a method for measuring APM and its degradation products,
including Phe, in soft drinks using LC–MS/MS. This method was used to measure APM and its
degradation products in regularly used soft drinks across Europe. We observed a large variation in the
amount of APM and its degradation products in the measured soft drinks. Also, substantial differences
were observed in the concentrations measured in similar soft drinks bought in different countries.
The mainstay of Phe-restricted diets is limiting the daily natural protein intake. One gram
of natural protein is considered to equal approximately 50 mg (or 303 µmol) of Phe [19]. Protein
tolerance, however, can differ significantly among patients, depending on, e.g., residual enzyme
activity, pregnancy, age, weight, and for hyperphenylalaninemias, also tetrahydrobiopterin (BH4)
responsiveness [1]. Healthy adults are used to consume approximately 70–120 g of natural protein a
day, whereas patients with a Phe-restricted diet are recommended to only consume 5–20 g of natural
protein, which is approximately equal to 250–1000 mg (or 1513–6054 µmol) Phe a day. Because of
their dietary Phe restriction, patients are told not to consume products containing APM. The results
of this study showed, however, a wide variety of APM and total Phe concentrations in soft drinks.
The APM and total Phe concentrations in our 95 APM-containing drinks ranged from 103 to 1790µmol/L
(30–527 mg/L) and from 119 to 2013 µmol/L (20–332 mg/L), respectively. APM concentrations were to
some extent comparable to concentrations reported earlier [9–16], except those reported by Zhu et al.,
who found significantly higher APM concentrations of 2826 and 7235 mg/L in two soft drinks [10].
However, none of the earlier studies measured as many soft drinks as our study did, nor similar soft
drinks of the same company from batches obtained from different countries. Sakai et al. also measured
DKP in three soft drinks, ranging from 1.6 to 2.9 mg/L, which is comparable to concentrations found in
our study [9]. The comparability of our results with those of other studies confirms the validity of
our data.
Including APM breakdown products is in our opinion essential to estimate the total original
APM amounts, as up to 51% of total Phe derived from non-APM Phe in the investigated soft drinks.
This is supported by the results of Barrado et al., who showed a very high Phe/APM ratio in two soft
drinks [13]. Analysis of only APM may therefore (highly) underestimate the total Phe content. Also of
interest is that APM concentrations were not detected in 16 non-APM-containing soft drinks, although
some did contain very small amounts of total Phe ranging from 0 to 12.5 µmol/L. In patients with
the lowest protein tolerance (5 g natural protein per day), consumption of one glass (200 mL) of an
APM-containing soft drink would correspond approximately to 0.4–26.4% of the daily allowable Phe
intake. Some APM-containing soft drinks should therefore indeed be seen as undesirable, but others
can be considered to have safe Phe concentrations for consumption by patients with milder deficiencies.
Nutrients 2020, 12, 1887 8 of 10
Please note that the amount of APM in the soft drinks presented in Supplemental Table S2 should be
taken with caution, as it is not clear whether and when manufacturers change their recipes. Furthermore,
it is important to note here that, mainly because of the high carbohydrate content, the consumption of
soft drinks in general is not considered to be part of a healthy diet.
Since the FDA approval for APM many years ago, the safety of APM has been studied extensively.
Numerous articles have been written regarding possible toxic, mutagenic, and carcinogenic effects [20].
Although the widespread debate on APM safety is ongoing, studies have been extensively reviewed
by the European Food Safety Authority (EFSA), who found no significant toxic effects and who
recommend dosages <40 mg/kg/day for non-PKU individuals [8]. Not only soft drinks, but also other
food products and several medications contain APM [8]. We did not investigate APM in other food
products or medications. However, as shown in this study, patients using Phe-restricted diets may be
able to consume some of the APM-containing soft drinks. In addition, it is possible that they will also
be able to safely consume some of the APM-containing foods and medicines if the amount of APM is
reported on the label. Of note, physicians should not hesitate to treat patients with APM-containing
medications, when this is considered necessary.
A limitation of this study is that we did not ask our representatives from different countries
for specific soft drinks. This would have improved the comparison of the APM amounts in soft
drinks between countries. Instead, we asked to send us the most regularly consumed soft drinks,
as applicability for patients was the main goal of our study. Furthermore, APM is unstable at high
temperatures and at low and high pH. The effect of short-term storage at 37 ◦C was also apparent from
the results of this study. The exact storage and transportation conditions of the samples before they
arrived at our laboratory are unknown and may have affected the APM concentrations, especially
if the samples were sent from warmer South European countries. However, by also measuring the
degradation products, the total Phe content in the soft drinks is expected to better reflect the added APM
amount. However, the total Phe concentration also decreased at 37 ◦C, although to a lesser extent than
that of APM. Our study did not include two other breakdown products of APM, i.e., Phe-methylester
and phenylalanylaspartate, which may also be sources of Phe in soft drinks. Their contribution to total
Phe is yet unknown but not likely to contribute to a higher extent compared to the metabolites tested.
The amount contributed by Phe-methylester seems to be very limited [7].
Another limitation of our study is that our method was designed primarily to analyze APM.
The measurement of the degradation products was a second aim. To analyze all metabolites in a single
run, higher limits of quantification for the degradation products were tolerated. In many samples,
these metabolites had concentrations below the LOQ (Phe 100%, DKP 40%, Asp–Phe 51%).
5. Conclusions
Our laboratory developed and validated a new method for measuring APM and its degradation
products in soft drinks. Regularly used soft drinks across Europe were shown to have varying amounts
of APM and Phe, even in comparable (clustered) soft drinks. Patients with hyperphenylalaninemias
and patients treated with NTBC can only consume limited amounts of Phe during the day. Since some
soft drinks had only low amounts of APM and Phe, patients should be able to consume these drinks.
Therefore, we strongly recommend national and international patient societies and advocacy groups to
call for the responsibility of companies to declare the amount of APM in their soft drinks.
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and clustered.
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